ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children

Authors

  • Mariane de Montalembert,

    Corresponding author
    1. Service de Pédiatrie Générale, Hôpital Necker-Enfants Malades, AP-HP, Paris, France; Centre de Référence de la Drépanocytose
    2. Université Paris Descartes, France
    • Mariane de Montalembert, Hopital Necker-Enfants Malades, 149 rue de Sevres, 75015 Paris, France
    Search for more papers by this author
  • Alina Ferster,

    1. Hémato-Oncologie Pédiatrique, Hôpital Universitaire des Enfants Reine Fabiola, U.L.B, Brussels, Belgium
    Search for more papers by this author
  • Raffaella Colombatti,

    1. Clinic of Pediatric Hematology-Oncology, Department of Pediatrics, University of Padova, Padova, Italy
    Search for more papers by this author
  • David C. Rees,

    1. Department of Paediatric Haematology, King's College London School of Medicine, King's College Hospital, London, United Kingdom
    Search for more papers by this author
  • Beatrice Gulbis,

    1. Department of Clinical Chemistry, Hôpital Erasme, U.L.B, Brussels, Belgium
    Search for more papers by this author
  • on behalf of the European Network for Rare and Congenital Anaemias


  • Conflict of interest: Nothing to report.

    The European network for rare and congenital anaemia (http://www.enerca.org) is cofunded by the European Commission through its Public Health and Consumer Protection Directorate. One of the goals of this network is to promote harmonization of procedures for diagnosis, treatment, and follow-up of patients with rare anemias. Through this network, clinical recommendations for pediatric sickle cell syndromes are proposed.

Ancillary